Patient characteristics
| Patient no. . | Age, y . | Underlying disease . | Conditioning therapy . | Transplantation modality . | Graft . | GVHD prophylaxis . | CMV disease prior to T-cell transfer . |
|---|---|---|---|---|---|---|---|
| 1 | 51 | AML, CR3 | Bu/Cy | Matched UD | BM | CSA/ATG/MMF/Pred | — |
| 2 | 30 | CML, BC | TBI/Cy/VP16 | 3 Ag mm sibling | CD34+PBPCs* | ATG | — |
| 3 | 45 | CML, AP | Bu/Cy | 1 Ag mm son | CD34+PBPCs | CSA/ATG | CMV colitis |
| 4 | 47 | CML, AP | TBI/Cy/TT | 1 Ag mm UD | BM | CSA/ATG/Pred | — |
| 5 | 45 | Ph+ ALL | TBI/Cy/VP16 | Matched UD | BM | CSA/ATG/MMF/Pred | — |
| 6 | 56 | AML, CR1 | Bu/Cy | HLA-id sibling | CD34+PBPCs | CSA | — |
| 7 | 41 | AML, CR1 | Bu/Cy/ARA-C | HLA-id sibling | CD34+PBPCs | CSA | CMV-IP |
| 8 | 33 | hg NHL PR2 | TBI/Cy | Matched UD | BM | CSA/ATG | — |
| Patient no. . | Age, y . | Underlying disease . | Conditioning therapy . | Transplantation modality . | Graft . | GVHD prophylaxis . | CMV disease prior to T-cell transfer . |
|---|---|---|---|---|---|---|---|
| 1 | 51 | AML, CR3 | Bu/Cy | Matched UD | BM | CSA/ATG/MMF/Pred | — |
| 2 | 30 | CML, BC | TBI/Cy/VP16 | 3 Ag mm sibling | CD34+PBPCs* | ATG | — |
| 3 | 45 | CML, AP | Bu/Cy | 1 Ag mm son | CD34+PBPCs | CSA/ATG | CMV colitis |
| 4 | 47 | CML, AP | TBI/Cy/TT | 1 Ag mm UD | BM | CSA/ATG/Pred | — |
| 5 | 45 | Ph+ ALL | TBI/Cy/VP16 | Matched UD | BM | CSA/ATG/MMF/Pred | — |
| 6 | 56 | AML, CR1 | Bu/Cy | HLA-id sibling | CD34+PBPCs | CSA | — |
| 7 | 41 | AML, CR1 | Bu/Cy/ARA-C | HLA-id sibling | CD34+PBPCs | CSA | CMV-IP |
| 8 | 33 | hg NHL PR2 | TBI/Cy | Matched UD | BM | CSA/ATG | — |
AML indicates acute myelocytic leukemia; CR, complete remission; Bu, busulfan; Cy, cyclophosphamide; UD, unrelated donor; BM, bone marrow; CSA, cyclosporin A; ATG, antithymocyte globulin; MMF, mycophenolate mofetil; Pred, prednisone; CML, chronic myeloid leukemia; BC, blast crisis; TBI, total-body irradiation; VP16, etoposide; mm, mismatched; PBPCs, peripheral blood progenitor cells; AP, accelerated phase; TT, thiotepa; Ph+, Philadelphia chromosome positive; ALL, acute lymphoblastic leukemia; HLA, human leukocyte antigen; id, identical; ARA-C, cytosine arabinoside; CMV-IP, CMV-induced interstitial pneumonitis; hg NHL, high-grade non-Hodgkin lymphoma; PR, partial remission.
Patient received less than 2 × 104CD3+ T cells/kg after CD34+ selection.